Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems

British Journal of Cancer

Volumn 107, Issue 10, 2012, Pages 1672-1677

  Shao, Y Y ^a,b   Lu, L C ^a   Lin, Z Z ^a   Hsu, C ^a   Shen, Y C ^a   Hsu, C H ^a,b   Cheng, A L ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Clinical trials; Hepatocellular carcinoma; Prognosis; Staging; Survival

Indexed keywords

ACCURACY; ADULT; ADVANCED CANCER; AGED; AMERICAN JOINT COMMITTEE ON CANCER SCORE; ARTICLE; BARCELONA CLINIC LIVER CANCER SCORE; CANCER OF THE LIVER ITALIAN PROGRAM SCORE; CANCER STAGING; CANCER SURVIVAL; CHINA INTEGRATED SCORE; CHINESE UNIVERSITY PROGNOSTIC INDEX SCORE; FEMALE; GROUPE D ETUDE ET DE TRAITEMENT DU CARCINOME HEPATOCELLULAIRE SCORE; HUMAN; INTERMETHOD COMPARISON; JAPAN INTEGRATED STAGING SCORE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OKUDA SCORE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TOKYO SCORE; TOURNOUX FACON SCORE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; YOUNG ADULT;

EID: 84869080379     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.466     Document Type: Article

References (28)

1. Cantarini MC, Trevisani F, Morselli-Labate AM, Rapaccini G, Farinati F, Del Poggio P, Di Nolfo MA, Benvegnu L, Zoli M, Borzio F, Bernardi M (2006) Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma. Am J Gastroenterol 101: 91-98. (Pubitemid 43381714)
2. Chen CH, Huang GT, Yang PM, Chen PJ, Lai MY, Chen DS, Wang JD, Sheu JC (2006) Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis. Eur J Cancer 42: 2524-2529.
3. Cheng A, Kang Y, Lin D, Park J, Kudo M, Qin S, Omata M, Pitman Lowenthal SW, Lanzalone S, Yang L, Lechuga M, Raymond E (2011) Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 29(suppl): Abstr 4000.
4. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34.
5. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C (1999) A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 31: 133-141. (Pubitemid 29287619)
6. Collette S, Bonnetain F, Paoletti X, Doffoel M, Bouche O, Raoul JL, Rougier P, Masskouri F, Bedenne L, Barbare JC (2008) Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Ann Oncol 19: 1117-1126. (Pubitemid 351796337)
7. Springer: New York Hsu CH, Shen YC, Lin ZZ, Chen PJ, Shao YY, Ding YH, Hsu C, Cheng AL (2010a) Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol Green FL, Page DL, Fleming ID (eds) (2002) Liver including intrahepatic bile ducts. In AJCC Cancer Staging Handbook. 6th edn pp 131-144. Springer: New York Hsu CH, Shen YC, Lin ZZ, Chen PJ, Shao YY, Ding YH, Hsu C, Cheng AL (2010a) Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol 53: 126-131.
8. Hsu CH, Yang TS, Hsu C, Toh HC, Epstein RJ, Hsiao LT, Chen PJ, Lin ZZ, Chao TY, Cheng AL (2010b) Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Brit J Cancer 102: 981-986.
9. Huitzil-Melendez FD, Capanu M, O'Reilly EM, Duffy A, Gansukh B, Saltz LL, Abou-Alfa GK (2010) Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol 28: 2889-2895.
10. Iizuka N, Oka M, Yamada-Okabe H, Mori N, Tamesa T, Okada T, Takemoto N, Tangoku A, Hamada K, Nakayama H, Miyamoto T, Uchimura S, Hamamoto Y (2002) Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res 62: 3939-3944. (Pubitemid 34791056)
11. Kudo M, Chung H, Osaki Y (2003) Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 38: 207-215. (Pubitemid 36527122)
12. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, Monges G, Thomas G, Bioulac-Sage P, Zucman-Rossi J (2001) Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 120: 1763-1773. (Pubitemid 32523494)
13. Leung TW, Tang AM, Zee B, Yu SC, Lai PB, Lau WY, Johnson PJ (2002a) Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferonalpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 94: 421-427. (Pubitemid 34081372)
14. Leung TWT, Tang AMY, Zee B, Lau WY, Lai PBS, Leung KL, Lau JTF, Yu SCH, Johnson PJ (2002b) Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system. Cancer 94: 1760-1769. (Pubitemid 34241115)
15. Lin ZZ, Hsu C, Hu FC, Shao YY, Chang DY, Yang CH, Hong RL, Hsu CH, Cheng AL (2012) Factors impacting prognosis prediction in BCLC Stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy. Oncologist 17: 970-977.
16. Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 19: 329-338.
17. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, Group SIS (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
18. Moinzadeh P, Breuhahn K, Stutzer H, Schirmacher P (2005) Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade Y results of an explorative CGH meta-Analysis. Br J Cancer 92: 935-941. (Pubitemid 40462642)
19. Okabe H, Ikai I, Matsuo K, Satoh S, Momoi H, Kamikawa T, Katsura N, Nishitai R, Takeyama O, Fukumoto M, Yamaoka Y (2000) Comprehensive allelotype study of hepatocellular carcinoma: potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and -negative tumors. Hepatology 31: 1073-1079. (Pubitemid 30233231)
20. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56: 918-928. (Pubitemid 15228292)
21. Shao YY, Chen PJ, Lin ZZ, Huang CC, Ding YH, Lee YH, Hsu CH, Cheng AL (2011) Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma. Anticancer Res 31: 4007-4011.
22. Shao YY, Lin ZZ, Hsu C, Lee KD, Hsiao CH, Lu YS, Huang CC, Shen YC, Hsu CH, Cheng AL (2012) Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma. Oncology 82: 59-66.
23. Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL (2010) Early alphafetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 116: 4590-4596.
24. Tateishi R (2005) Proposal of a new prognostic model for hepatocellular carcinoma: An analysis of 403 patients. Gut 54: 419-425. (Pubitemid 40299102)
25. The Cancer of the Liver Italian Program investigators (1998) A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients. Hepatology 28: 751-755.
26. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
27. Tournoux-Facon C, Paoletti X, Barbare JC, Bouche O, Rougier P, Dahan L, Lombard-Bohas C, Faroux R, Raoul JL, Bedenne L, Bonnetain F (2011) Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting. J Hepatol 54: 108-114.
28. Zhang BH, Wang XH, Yue HY, Ling CQ (2010) A new staging system is more discriminant than conventional staging systems for unresectable hepatocellular carcinoma. J Cancer Res Clin Oncol 136: 821-827